News

Article

Ripple Therapeutics and AbbVie collaborate in development of RTC-620 for IOP reduction in patients with open-angle glaucoma

Ripple will lead preclinical development of RTC-620 while AbbVie will lead the clinical and commercialization activities upon exercise of option-to-license agreement.

(Image Credit: AdobeStock/Parradee)

(Image Credit: AdobeStock/Parradee)

Ripple Therapeutics has announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620.

RTC-620 is a “next generation,” fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).1

The collaboration leverages “AbbVie's expertise in eye care and Ripple's innovative drug delivery platform.”

According to Ripple, its patented technology platform is based on a “discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients.” Repeat dosing is supported by there being no polymers or excipients, which according to the company means that once the drug is gone, the implant is gone with no pro-inflammatory degradation products.1

Tom Reeves, President and CEO of Ripple Therapeutics commented on the partnership in a press release from the company stating, "By combining our drug delivery platform with AbbVie's research, clinical, regulatory and commercial capabilities, we hope to deliver a meaningful impact on the lives of people living with glaucoma."

Under the terms of the agreement, Ripple will lead preclinical development of RTC-620. AbbVie will lead the clinical and commercialization activities upon exercise of the option. Ripple will also receive an upfront payment of $21.8 million from AbbVie and is eligible to receive up to $290 million in aggregate option fees and milestones, as well as tiered royalties on net sales.1

References:
  1. Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management. Press Release; September 17, 2024. Accessed September 18, 2024. https://www.accesswire.com/918653/ripple-therapeutics-announces-collaboration-and-option-to-license-agreement-with-abbvie-to-develop-next-generation-therapies-for-glaucoma-management
Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
© 2024 MJH Life Sciences

All rights reserved.